BT 3228 | 2015
Biotechnology
BLOOD SCREENING MARKET BY TECHNOLOGY (NUCLEIC ACID AMPLIFICATION TEST, ELISA, RAPID TEST, CHEMILUMINESCENCE IMMUNOASSAY, NEXT GENERATION SEQUENCING, WESTERN BLOTTING), PRODUCT (INSTRUMENT, REAGENT) & END USER (BLOOD BANK, HOSPITAL)
FORECASTS TO 2019 Report Description
Table of Contents List of Tables Sample Tables Related Reports
MarketsandMarkets North - Dominion Plaza, 17304, Preston Road, Suite 800, Dallas, TX 75252, U.S. Tel. No.: 1-888-600-6441 Email: sales@marketsandmarkets.com Website: www.marketsandmarkets.com
Blood Screening Market – Forecasts to 2019
BT 3228
MarketsandMarkets is a global market research and consulting company based in the U.S. We publish strategically analyzed market research reports and serve as a business intelligence partner to Fortune 500 companies across the world. MarketsandMarkets also provides multi-client reports, company profiles, databases, and custom research services. MarketsandMarkets covers fourteen industry verticals, including aerospace and defence, advanced materials, automotives and transportation, banking and financial services, biotechnology, chemicals, consumer goods, energy and power, food and beverages, industrial automation, medical devices, pharmaceuticals, semiconductor and electronics, and telecommunications and IT.
Copyright Š 2014 MarketsandMarkets All Rights Reserved. This document contains highly confidential information and is the sole property of MarketsandMarkets. No part of it may be circulated, copied, quoted, or otherwise reproduced without the approval of MarketsandMarkets.
1 Š MarketsandMarkets
Blood Screening Market – Forecasts to 2019
1
INTRODUCTION
1.1
OBJECTIVES OF THE STUDY
1.2
BT 3228
To define and segment the global blood screening market on the basis of technologies, products and services, end users, and regions
To identify and analyze the market dynamics for the blood screening market
To analyze and forecast the blood screening market, by value
To analyze and forecast the various blood screening products in each region, by value
To estimate the number of tests (ELISA and NAT) performed worldwide
To analyze the opportunities in the market for stakeholders by identifying the high-growth segments
To strategically profile the key players in the market and comprehensively analyze their core competencies1 and market shares
To track and analyze competitive developments such as joint ventures, alliances, mergers and acquisitions, and new product/technology developments in the market
MARKET DEFINITION
Blood screening is a medical process in which donated blood is mainly tested for HIV1, HIV2, HBV, HCV, malaria, and syphilis. Donated blood is screened for these infectious diseases to reduce the risk of transfusion-transmitted infections (TTIs).
___________________________________ Note: 1 Core competencies of the companies are captured in terms of the key developments, SWOT analyses, and key strategies adopted by them to sustain their positions in the market.
2 © MarketsandMarkets
Blood Screening Market – Forecasts to 2019
1.3
BT 3228
MARKET SCOPE
This market study covers various blood screening products and services, including instruments, reagents, software, and services. It also covers the blood screening technology market, including NAT, ELISA, Enzyme Immunoassays (EIAs) and chemiluminescent immunoassays (CLIAs), and NGS and western blot assays.
This market study covers blood screening of donated blood before transfusion.
This study does not include blood testing in clinical or pathological conditions.
1.3.1
MARKETS COVERED
This research report categorizes the blood screening market into the following segments and subsegments.
Blood Screening Market, by Technology
Nucleic Acid Amplification Test (NAT)
ELISA
Enzyme Immunoassays (EIAs) and Chemiluminescent Immunoassays (CLIAs)
NGS
Western Blot Assays
Blood Screening Instruments Market, By Products and Services Blood Screening Market, by Products and Services
Instruments (Hardware)
Reagents
Purchase Modes
ELISA Reagents
NAT Reagents
Rental Purchase
Immunosorbent
Enzymes and Polymerases
Outright Purchase
Conjugate
Probes & Primers
Substrate
Buffers, Nucleotides, & Solutions
Controls
Labeling & Detection Reagents
Sample Diluent and Wash Solution
Standards and Controls
Software & Services
Other Reagents
Note: Others include reagents used in Enzyme Immunoassays (EIAs) and chemiluminescent immunoassays (CLIAs) and reagents used in western blot assays. Source: Annual Reports, SEC Filings, Press Releases, Investor Presentations, World Health Organization (WHO), United States Food and Drug Administration (USFDA), Centers for Disease Control and Prevention (CDC), Red Cross Society, AVERT, Expert Interviews, and MarketsandMarkets Analysis
3 © MarketsandMarkets
Blood Screening Market – Forecasts to 2019
BT 3228
Blood Screening Market, by End User
Blood Banks
Hospitals
Blood Screening Market, by Region
North America
Europe
Asia
Rest of the World (RoW)
1.3.2
YEARS CONSIDERED FOR THE STUDY Historical Years
2012–2013
Base Year
2013
Projected Year
2019
Forecast Period
2014–2019
1.4
CURRENCY
The currency used for this report is USD ($), with market size indicated in $million.
For companies reporting their revenues in USD, the revenues were picked from their annual reports
For companies that reported their revenues in other currencies, the average annual currency conversion rate was used for that particular year to convert the value to USD
1.5
LIMITATIONS
Due to limited information available from primary and secondary sources, the report does not cover:
Quantitative information (Market Value) at the country level for the RoW region
The market size of ELISA, NAT and other reagents at regional level
1.6
STAKEHOLDERS
Blood screening instruments and reagents manufacturers
Blood screening software and services providers
Blood banks
Hospitals
Red Cross societies
Regulatory bodies
Research and consulting firms
4 © MarketsandMarkets
Blood Screening Market – Forecasts to 2019
BT 3228
2
RESEARCH METHODOLOGY
2.1
RESEARCH DATA
This research study involved the usage of extensive secondary sources; directories; databases such as Hoovers, Bloomberg Businessweek, Factiva, and OneSource; white papers; annual reports; and SEC filings of companies. Secondary research was mainly used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the global blood screening market. It was also used to obtain key information about the major players, market classification, and segmentation according to the industry trends, regional markets, and developments related to the market and technology perspectives. Primary sources involved in this research study are industry experts from core and related industries; preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and laboratory technicians; and organizations related to all the segments of this industry‘s value chain. In-depth interviews were conducted from various primary respondents such as key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants to obtain and verify critical qualitative and quantitative information as well as to assess future growth prospects. The following figure shows the market research methodology applied in making this report.
FIGURE 1
RESEARCH METHODOLOGY
HISTORICAL DATA FOR THE BLOOD SCREENING MARKET
Market Share Analysis
Regulatory Landscape
Competitive Landscape
Evolution
Company Revenues and R&D Expenses
Regional Usage Pattern
Market Drivers:
Market Restraints:
• Increasing number of blood donations and blood donors
•
• Rising awareness regarding blood donation • Increasing Patients’ capacity to pay for NAT tested blood
• Rising adoption of NAT testing • Increasing demand for donated blood
INFLUENCING FACTORS
• Increasing prevalence/incidence of infectious diseases
• •
Capital expenditure and operating costs of NAT testing Instrument NAT testing is not mandatory in developing countries Digital immunoassay as an alternative technology
(Market Trends and Dynamics) Market Opportunities:
• • •
FORECAST
Challenges:
Pathogen reduction technology Microbiology screening (blood screening for addition tests), an emerging opportunity in blood screening Multiplexing (Single test for all the HIV, HBV, HCV) , an emerging opportunity
Historical Data of the Market Impact Analysis of Market Trends
• • •
Market Size & Forecast, by Technology Market Size & Forecast, by Products and Services
High cost of blood screening test Dearth of trained professionals Regulatory challenges
Arrive at the Market Size, Share, and CAGR for the Blood Screening Market (2014-2019)
Market Size & Forecast, by End User
In the secondary research process, various secondary sources were referred to for identifying and collecting information useful for this study. The secondary sources include annual reports, press releases, 5 © MarketsandMarkets
Blood Screening Market – Forecasts to 2019
BT 3228
investor presentations of companies, white papers, medical device journals, certified publications, articles from recognized authors, gold standard and silver standard websites, directories, and databases. Secondary research was mainly used to obtain key information about the industry‘s supply chain, leading and emerging players, market classification and segmentation according to the industry trends to the bottom-most level, regional markets, and key developments from both market and technology oriented perspectives. In the primary research process, various primary sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing directors, technology and innovation directors, and related key executives from various key companies and organizations operating in the blood screening market. Primary sources from the demand side include executives, technicians and doctors from blood banks, and members of the Red Cross societies. After the complete market engineering (which includes calculations for market statistics, market breakdown, market size estimations, market forecasting, and data triangulation), extensive primary research was conducted to gather information and to verify and validate the critical numbers arrived at. Primary research was also conducted to identify and study the segmentation types; industry trends; Porter‘s analysis; key players; competitive landscape for blood screening market and end products supplied by different market players; and key market dynamics such as drivers, restraints, opportunities, and key player strategies. In the complete market engineering process, both top-down and bottom-up approaches were extensively used along with several data triangulation methods to perform market estimation and market forecasting for the overall market segments and subsegments listed in this report. Extensive qualitative and quantitative analysis was performed on the complete market engineering process to list the key information/insights throughout the report.
2.2
SECONDARY DATA
2.2.1
KEY DATA FROM SECOND ARY SOURCES SECONDARY SOURCES
DATA
Company Financials Magazines Journals Press Releases Paid Databases MarketsandMarkets Data Repository
1
Market Size
2
Revenue of Companies
Annual Reports Company Websites Public Databases MarketsandMarkets Data Repository
Company Websites Annual Reports Press Releases MarketsandMarkets Data Repository
3
Qualitative Information (Market Dynamics and Trends)
6 © MarketsandMarkets
Blood Screening Market – Forecasts to 2019
2.3
PRIMARY DATA
2.3.1
KEY DATA FROM PRIMAR Y SOURCES PARAMETER
1
2
3
BT 3228
Regional Split
Global Market Size
Market Split
Overall market and segments in 2014
CAGR of each region in the forecast period (2014–2019)
Global market size for 2014 CAGR for the forecast period (2014–2019)
By NAT, ELISA, Enzyme Immunoassays (EIAs) and chemiluminescent immunoassays (CLIAs), NGS, and Western blot assays By Instruments, reagents, software and services
2.3.2
DATA Global blood screening market, by geography – North America, Europe, Asia, and RoW
Global blood screening market Blood screening market by segment Blood screening market, by technology, products and services, and end user
Blood screening market, by technology Blood screening market, by products and services
Blood screening market, by end user
KEY INDUSTRY INSIGHTS
“NAT accounted for ~XX% of the global blood screening market.” President and CEO, -- Leading NAT Instrument Manufacturer
“The market for blood screening reagents is expected to grow at a higher rate of XX% to XX% in the next five years.”
– Sales Director, Leading Blood Screening Reagents/Kits Manufacturer
“The blood screening market is expected to grow at a rate of XX% to XX%.” – CEO, Leading Blood Screening Instruments/Reagents Manufacturing Company
“Emerging markets such as India and China unfold new avenues for growth of the blood screening market due to the growing number of blood donations and blood donors.” –Director (APAC), Leading Blood Screening Instruments/Reagents Manufacturing Company
7 © MarketsandMarkets
Blood Screening Market – Forecasts to 2019
BT 3228
2.3.3
BREAKDOWN OF PRIMARI ES
FIGURE 2
BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
NUMBER OF PRIMARIES: BY COMPANY TYPE
NUMBER OF PRIMARIES: BY DESIGNATION
NUMBER OF PRIMARIES: BY REGION
XX XX XX
XX
XX
XX
XX
XX Tier 1 Companies
XX Tier 2 Companies
Tier 3 Companies
C Level
Director Level
XX
Others
North America
Europe
Asia
RoW
Note: *Others include sales managers, marketing managers, and product managers Tier of the companies are defined on the basis of their total revenue. As of 2013: Tier 1 = > $XX Billion, Tier 2 = $XX Million–$XX Billion, and Tier 3 = < $XX Million
2.4
MARKET SIZE ESTIMATION
2.4.1
BOTTOM-UP APPROACH
To estimate the size of the market, the global blood screening market size was obtained from annual reports, SEC filings, online publications, and extensive primary interviews. A percentage split was applied to arrive at the market size for the product types. A further split was applied to arrive at the market size for each subsegment. The percentage splits were validated by primary participants. The country-level market that was obtained from annual reports, SEC filings, online publications, and extensive primary interviews was added up to reach the total market size for North America, Europe, Asia, and RoW. By adding up the market sizes of all these regions the global blood screening market was derived.
8 © MarketsandMarkets
Blood Screening Market â&#x20AC;&#x201C; Forecasts to 2019
FIGURE 3
BT 3228
BOTTOM-UP APPROACH Bottom-up Approach
Global Blood Screening Market
Global Blood Screening Market
The Blood Screening Market for Each Region (North America, Europe, Asia, and RoW) Was Added up
Primary: Demand and Supply Side Experts Secondary: Annual Reports, Presentations, Press Releases, Journals, Paid Databases, and MarketsandMarkets Repository
Country-level Markets for Blood Screening Were Added up to Reach the Regional Market
2.4.2
TOP-DOWN APPROACH
Both, top-down and bottom-up approaches were used to estimate and validate the size of the global market and to estimate the size of various other dependent submarkets in the overall blood screening market. The key players in this market were identified through secondary research and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares, splits, and breakdowns were determined by using secondary sources and verified through primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. This data was consolidated and added with detailed inputs and analysis from MarketsandMarkets and presented in this report. The following figure shows an illustrative representation of the overall market size estimation process employed for the purpose of this study.
9 Š MarketsandMarkets
Blood Screening Market â&#x20AC;&#x201C; Forecasts to 2019
FIGURE 4
TOP-DOWN APPROACH Top-down Approach
Global Blood Screening Market ($Million)
Percentage Splits for the Segments of the Blood Screening Market
Regional Splits
Regional and Country-wise Markets for Each Segment
2.5
BT 3228
Global Blood Screening Market The Global Market Size is Validated Through Primaries (Demand and Supply Side Experts) Secondary: Annual Reports, Presentations, Press Releases, Journals, Paid Databases, and MarketsandMarkets Repository Primary: Demand and Supply Side Experts
Primary: Demand and Supply Side Experts Secondary: Company Websites, Press Releases, and News Articles
Secondary: Annual Reports, Presentations, Press Releases, Journals, Paid Databases, and MarketsandMarkets Repository Primary: Demand and Supply Side Experts
MARKET BREAKDOWN AND DATA TRIANGULATION
After arriving at the overall market size from the estimation process explained above, the total market was split into several segments and subsegments. In order to complete the overall market engineering process and to arrive at the exact statistics for all the segments and subsegments, data triangulation and market crackdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides. Along with this, the market was validated using both top-down and bottom-up approaches.
10 Š MarketsandMarkets
Blood Screening Market – Forecasts to 2019
FIGURE 5
BT 3228
DATA TRIANGULATION METHODOLOGY
Demand Side
PRIMARY SOURCES
SECONDARY SOURCES
Interviews with: •
Directors and Operational Heads in Blood Banks and Hospitals
•
Technologists, Physicians, Consultants, and Technicians
•
Purchase Managers in Blood Banks and Hospitals
Annual Reports, Presentations, Websites and Press Releases of Top Players, News Articles, Journals, and Paid Databases
MnM KNOW*
Supply Side
Interviews with: •
CEOs
•
Vice Presidents
•
Marketing Directors
•
Technology and Innovation Directors and Related Key Executives From Various Key Companies and Organizations Operating in the Blood Screening Market
Secondary Sources
Primary Sources
Key Players
•
World Health Organization (WHO)
•
Centers for Disease Control and Prevention (CDC)
•
National Institutes of Health (NIH)
•
Red Cross Societies
DATA TRIANGULATION
Information Sourced Opportunities and Challenges
Competitive Landscape
Drivers and Restraints
Forecast
Market Size (2013) and Market Share (2013)
Regional Analysis
MnM KNOW* stands for ‘MarketsandMarkets Knowledge Asset Management' framework. In this context, it stands for The existing market research knowledge repository of over 5,000 granular markets, our flagship competitive intelligence and market research platform "RT", subject-matter experts, and independent consultants. MnM KNOW acts as an independent source that helps us validate information gathered from primary and secondary sources.
2.6
MARKET SHARE ESTIMATION
The market shares for the key players have been calculated on the basis of secondary data available through paid and unpaid sources and by analyzing the product portfolios of the top companies. This data was further validated through expert interviews.
2.7
ASSUMPTIONS FOR THE STUDY PARAMETER
1
Market Growth
2
Market Share Analysis, by Key Player
ASSUMPTION The CAGR for the forecast period is assumed to be normalized and the effect of inflation, recession, economic downturn, regulatory or policy changes, or other factors are not considered.
Base year for calculation of market share analysis, by key player, is 2013.
11 © MarketsandMarkets
Blood Screening Market – Forecasts to 2019
BT 3228
TABLE OF CONTENTS 1
2
INTRODUCTION ........................................................................................................ 20 1.1
OBJECTIVES OF THE STUDY ...........................................................................................................20
1.2
MARKET DEFINITION.....................................................................................................................20
1.3
MARKET SCOPE............................................................................................................................21 1.3.1
MARKETS COVERED ....................................................................................................... 21
1.3.2
YEARS CONSIDERED FOR THE STUDY .............................................................................. 22
1.4
CURRENCY ...................................................................................................................................22
1.5
LIMITATIONS ................................................................................................................................22
1.6
STAKEHOLDERS ...........................................................................................................................22
RESEARCH METHODOLOGY ...................................................................................... 23 2.1
RESEARCH DATA ..........................................................................................................................23
2.2
SECONDARY DATA ........................................................................................................................24 2.2.1
2.3
2.4
KEY DATA FROM SECONDARY SOURCES ......................................................................... 24
PRIMARY DATA .............................................................................................................................25 2.3.1
KEY DATA FROM PRIMARY SOURCES .............................................................................. 25
2.3.2
KEY INDUSTRY INSIGHTS ................................................................................................ 25
2.3.3
BREAKDOWN OF PRIMARIES .......................................................................................... 26
MARKET SIZE ESTIMATION ............................................................................................................26 2.4.1
BOTTOM-UP APPROACH ................................................................................................. 26
2.4.2
TOP-DOWN APPROACH................................................................................................... 27
2.5
MARKET BREAKDOWN AND DATA TRIANGULATION ........................................................................28
2.6
MARKET SHARE ESTIMATION ........................................................................................................29
2.7
ASSUMPTIONS FOR THE STUDY ....................................................................................................29
3
EXECUTIVE SUMMARY .............................................................................................. 30
4
PREMIUM INSIGHTS ................................................................................................ 35 4.1
BLOOD SCREENING MARKET, BY TECHNOLOGY .............................................................................35
4.2
BLOOD SCREENING MARKET, BY PRODUCTS AND SERVICES .........................................................36
4.3
BLOOD SCREENING REAGENTS MARKET .......................................................................................37
4.4
BLOOD SCREENING ELISA MARKET...............................................................................................38
4.5
BLOOD SCREENING MARKET, BY END USER ..................................................................................39
4.6
GEOGRAPHIC SNAPSHOT .............................................................................................................40
12 © MarketsandMarkets
Blood Screening Market – Forecasts to 2019
5
MARKET OVERVIEW.................................................................................................. 41 5.1
INTRODUCTION ............................................................................................................................42
5.2
MARKET SEGMENTATION ..............................................................................................................42
5.3
5.2.1
BY TECHNOLOGY ............................................................................................................ 42
5.2.2
BY PRODUCTS AND SERVICES ........................................................................................ 43
5.2.3
BY END USER ................................................................................................................. 43
5.2.4
BY REGION ..................................................................................................................... 44
MARKET DYNAMICS......................................................................................................................45 5.3.1
5.3.2
5.3.3
5.3.4
6
BT 3228
DRIVERS ........................................................................................................................ 45 5.3.1.1
Increasing number of blood donations and blood donors .................................... 45
5.3.1.2
Rising awareness regarding the safety of donated blood ..................................... 46
5.3.1.3
Increasing affordability for NAT due to rising disposable incomes ....................... 46
5.3.1.4
Growing adoption of NAT for blood screening ..................................................... 46
5.3.1.5
Increasing demand of donated blood ................................................................. 46
5.3.1.6
Rising prevalence of infectious diseases ............................................................ 47
RESTRAINTS................................................................................................................... 48 5.3.2.1
Capital expenditure and operating costs of NAT .................................................. 48
5.3.2.2
Lack of mandates for NAT in developing countries .............................................. 49
5.3.2.3
Emergence of alternative technologies such as digital immunoassay .................. 49
OPPORTUNITIES ............................................................................................................. 50 5.3.3.1
Pathogen reduction technology.......................................................................... 50
5.3.3.2
Microbiology screening...................................................................................... 50
5.3.3.3
Multiplexing (single test for HIV, HBV, & HCV) ..................................................... 50
CHALLENGES ................................................................................................................. 51 5.3.4.1
Price reduction .................................................................................................. 51
5.3.4.2
Lack of trained manpower.................................................................................. 51
5.3.4.3
Regulatory challenges ....................................................................................... 51
INDUSTRY INSIGHTS ................................................................................................ 52 6.1
SUPPLY CHAIN ANALYSIS .............................................................................................................52
6.2
PEST ANALYSIS ............................................................................................................................53
6.3
6.2.1
POLITICAL FACTORS ....................................................................................................... 53
6.2.2
ECONOMIC FACTORS ..................................................................................................... 53
6.2.3
SOCIAL FACTORS ........................................................................................................... 54
6.2.4
TECHNICAL FACTORS ..................................................................................................... 54
PORTER’S FIVE FORCE ANALYSIS ..................................................................................................55 6.3.1
THREAT OF NEW ENTRANTS ............................................................................................ 55
6.3.2
THREAT OF SUBSTITUTE TECHNOLOGIES ......................................................................... 56
6.3.3
BARGAINING POWER OF SUPPLIERS .............................................................................. 56
6.3.4
BARGAINING POWER OF BUYERS ................................................................................... 56
6.3.5
INTENSITY OF COMPETITIVE RIVALRY .............................................................................. 56
13 © MarketsandMarkets
Blood Screening Market – Forecasts to 2019
7
BLOOD SCREENING MARKET, BY TECHNOLOGY ........................................................ 57 7.1
INTRODUCTION ............................................................................................................................58
7.2
BLOOD SCREENING MARKET, BY VOLUME (NUMBER OF TESTS CONDUCTED) ................................59
7.3
NUCLEIC ACID TEST (NAT) .............................................................................................................60
7.4
8
7.3.1
TRANSCRIPTION-MEDIATED AMPLIFICATION (TMA) ......................................................... 63
7.3.2
REAL-TIME POLYMERASE CHAIN REACTION (PCR) ........................................................... 65
ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA).......................................................................68 7.4.1
RAPID TEST (CARD METHODOLOGY) ................................................................................ 70
7.4.2
1ST GENERATION ELISA ................................................................................................. 72
7.4.3
2ND GENERATION ELISA ................................................................................................ 74
7.4.4
3RD GENERATION ELISA................................................................................................. 76
7.4.5
4TH GENERATION ELISA ................................................................................................. 78
7.5
ENZYME IMMUNOASSAYS (EIAS) AND CHEMILUMINESCENT IMMUNOASSAYS (CLIAS) ..................81
7.6
NEXT-GENERATION SEQUENCING (NGS) ........................................................................................83
7.7
WESTERN BLOT ASSAY .................................................................................................................85
BLOOD SCREENING MARKET, BY PRODUCTS AND SERVICES .................................... 88 8.1
INTRODUCTION ............................................................................................................................89
8.2
REAGENTS ...................................................................................................................................90 8.2.1
8.2.2
8.2.3
8.3
8.4
9
BT 3228
ELISA REAGENTS............................................................................................................ 92 8.2.1.1
Immunosorbent................................................................................................. 95
8.2.1.2
Controls ............................................................................................................ 95
8.2.1.3
Conjugate (Antigen or antibody conjugated enzyme) ........................................... 95
8.2.1.4
Substrate (Substrate of enzyme) ........................................................................ 95
8.2.1.5
Sample diluents and wash solutions .................................................................. 96
NAT REAGENTS .............................................................................................................. 96 8.2.2.1
Enzymes and Polymerases ................................................................................. 99
8.2.2.2
Standards and Controls ..................................................................................... 99
8.2.2.3
Probes and Primers ........................................................................................... 99
8.2.2.4
Buffers, Nucleotides and Solutions .................................................................... 99
8.2.2.5
Labeling and Detection Reagents....................................................................... 99
OTHER REAGENTS ........................................................................................................100
INSTRUMENTS (HARDWARE).......................................................................................................101 8.3.1
RENTAL PURCHASE ......................................................................................................104
8.3.2
OUTRIGHT PURCHASE ..................................................................................................104
SOFTWARE AND SERVICES .........................................................................................................104
BLOOD SCREENING MARKET, BY END USER ........................................................... 107 9.1
INTRODUCTION ..........................................................................................................................108
9.2
BLOOD BANKS ...........................................................................................................................109
9.3
HOSPITALS.................................................................................................................................112
14 © MarketsandMarkets
Blood Screening Market – Forecasts to 2019
BT 3228
10 BLOOD SCREENING MARKET, BY REGION ............................................................... 115 10.1
INTRODUCTION ..........................................................................................................................116
10.2
NORTH AMERICA ........................................................................................................................119
10.3
10.4
10.5
10.2.1
U.S. .............................................................................................................................122
10.2.2
CANADA.......................................................................................................................125
EUROPE .....................................................................................................................................127 10.3.1
GERMANY ....................................................................................................................130
10.3.2
FRANCE .......................................................................................................................133
10.3.3
U.K. .............................................................................................................................136
10.3.4
ITALY............................................................................................................................139
10.3.5
SPAIN ..........................................................................................................................141
10.3.6
REST OF EUROPE (ROE) ................................................................................................145
ASIA...........................................................................................................................................148 10.4.1
JAPAN ..........................................................................................................................150
10.4.2
CHINA ..........................................................................................................................153
10.4.3
INDIA ...........................................................................................................................156
10.4.4
REST OF ASIA (ROA) .....................................................................................................159
REST OF THE WORLD (ROW) ........................................................................................................162
11 COMPETITIVE LANDSCAPE ..................................................................................... 166 11.1
OVERVIEW ..................................................................................................................................166
11.2
MARKET SHARE ANALYSIS ..........................................................................................................167
11.3
11.2.1
MARKET SHARE ANALYSIS FOR NAT ..............................................................................167
11.2.2
MARKET SHARE ANALYSIS FOR BLOOD SCREENING......................................................168
COMPETITIVE SITUATIONS AND TRENDS......................................................................................169 11.3.1
NEW PRODUCT LAUNCHES ...........................................................................................170
11.3.2
MERGERS AND ACQUISITIONS .....................................................................................171
11.3.3
REGULATORY APPROVALS ............................................................................................172
11.3.4
PARTNERSHIPS AND AGREEMENTS ..............................................................................173
12 COMPANY PROFILES .............................................................................................. 174 (Overview, Financials, Products & Services, Strategy, & Developments)*
12.1
INTRODUCTION ..........................................................................................................................174
12.2
GRIFOLS ....................................................................................................................................175
12.3
ROCHE DIAGNOSTICS (A DIVISION OF F. HOFFMANN-LA ROCHE LTD) ...........................................178
12.4
ABBOTT LABORATORIES .............................................................................................................181
12.5
BIOMÉRIEUX ..............................................................................................................................184
12.6
BIO-RAD LABORATORIES, INC.....................................................................................................187
12.7
SIEMENS HEALTHCARE (SUBSIDIARY OF SIEMENS AG) ...............................................................190
12.8
ORTHO-CLINICAL DIAGNOSTICS, INC. .........................................................................................192
12.9
THERMO FISHER SCIENTIFIC, INC. ..............................................................................................194 15
© MarketsandMarkets
Blood Screening Market – Forecasts to 2019
BT 3228
12.10
BECKMAN COULTER (SUBSIDIARY OF DANAHER CORPORATION) .................................................196
12.11
BECTON, DICKINSON AND COMPANY ..........................................................................................198
*Details on Financials, Product & Services, Strategy, & Developments might not be captured in case of unlisted companies.
13 APPENDIX .............................................................................................................. 200 13.1
INSIGHTS OF INDUSTRY EXPERTS ...............................................................................................200
13.2
DISCUSSION GUIDE ...................................................................................................................201
13.3
AVAILABLE CUSTOMIZATIONS .....................................................................................................204
13.4
INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE .................................................................204
13.5
RELATED REPORTS .....................................................................................................................205
16 © MarketsandMarkets
Blood Screening Market – Forecasts to 2019
BT 3228
LIST OF TABLES U
TABLE 1
BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2012–2019 ($MILLION)
58
TABLE 2
GLOBAL BLOOD SCREENING MARKET, BY VOLUME (NUMBER OF TESTS), 2014
59
TABLE 3
NORTH AMERICA: BLOOD SCREENING MARKET, BY VOLUME (NUMBER OF TESTS), 2014
59
TABLE 4
EUROPE: BLOOD SCREENING MARKET, BY VOLUME (NUMBER OF TESTS),2014
59
TABLE 5
ASIA: BLOOD SCREENING MARKET, BY VOLUME (NUMBER OF TESTS), 2014
60
TABLE 6
BLOOD SCREENING NAT TECHNOLOGY MARKET SIZE, BY REGION, 2012–2019 ($MILLION)
61
NORTH AMERICA: BLOOD SCREENING NAT TECHNOLOGY MARKET SIZE, BY COUNTRY, 2012–2019 ($MILLION)
62
EUROPE: BLOOD SCREENING NAT TECHNOLOGY MARKET SIZE, BY COUNTRY/REGION, 2012–2019 ($MILLION)
62
ASIA: BLOOD SCREENING NAT TECHNOLOGY MARKET SIZE, BY COUNTRY/REGION, 2012–2019 ($MILLION)
63
BLOOD SCREENING NAT TECHNOLOGY MARKET SIZE, BY TYPE, 2012–2019 ($MILLION)
63
TRANSCRIPTION-MEDIATED AMPLIFICATION TECHNOLOGY MARKET SIZE, BY REGION, 2012–2019 ($MILLION)
64
NORTH AMERICA: TRANSCRIPTION-MEDIATED AMPLIFICATION TECHNOLOGY MARKET SIZE, BY COUNTRY, 2012–2019 ($MILLION)
64
EUROPE: TRANSCRIPTION-MEDIATED AMPLIFICATION TECHNOLOGY MARKET SIZE, BY COUNTRY/REGION, 2012–2019 ($MILLION)
65
ASIA: TRANSCRIPTION-MEDIATED AMPLIFICATION TECHNOLOGY MARKET SIZE, BY COUNTRY/REGION, 2012–2019 ($MILLION)
65
TABLE 15
REAL-TIME PCR TECHNOLOGY MARKET SIZE, BY REGION, 2012–2019 ($MILLION)
66
TABLE 16
NORTH AMERICA: REAL-TIME PCR TECHNOLOGY MARKET SIZE, BY COUNTRY, 2012–2019 ($MILLION)
66
EUROPE: REAL-TIME PCR TECHNOLOGY MARKET SIZE, BY COUNTRY/REGION, 2012–2019 ($MILLION)
67
ASIA REAL-TIME PCR TECHNOLOGY MARKET SIZE, BY COUNTRY/REGION, 2012–2019 ($MILLION)
67
TABLE 19
ELISA MARKET SIZE, BY REGION, 2012–2019 ($MILLION)
68
TABLE 20
NORTH AMERICA: ELISA MARKET SIZE, BY COUNTRY, 2012–2019 ($MILLION)
68
TABLE 21
EUROPE: ELISA MARKET SIZE, BY COUNTRY/REGION, 2012–2019 ($MILLION)
69
TABLE 22
ASIA: ELISA MARKET SIZE, BY COUNTRY/REGION, 2012–2019 ($MILLION)
69
TABLE 23
ELISA MARKET SIZE, BY TYPE, 2012–2019 ($MILLION)
70
TABLE 24
RAPID TEST (CARD METHODOLOGY) MARKET SIZE, BY REGION, 2012–2019 ($MILLION)
70
NORTH AMERICA: RAPID TEST (CARD METHODOLOGY) MARKET SIZE, BY COUNTRY, 2012–2019 ($MILLION)
71
EUROPE: RAPID TEST (CARD METHODOLOGY) MARKET SIZE, BY COUNTRY/REGION, 2012–2019 ($MILLION)
71
ASIA: RAPID TEST (CARD METHODOLOGY) MARKET SIZE, BY COUNTRY/REGION, 2012–2019 ($MILLION)
72
1ST GENERATION ELISA MARKET SIZE, BY REGION, 2012–2019 ($MILLION)
72
TABLE 7 TABLE 8 TABLE 9 TABLE 10 TABLE 11 TABLE 12 TABLE 13 TABLE 14
TABLE 17 TABLE 18
TABLE 25 TABLE 26 TABLE 27 TABLE 28
17 © MarketsandMarkets
Blood Screening Market – Forecasts to 2019
TABLE 29
BT 3228
NORTH AMERICA: 1ST GENERATION ELISA MARKET SIZE, BY COUNTRY, 2012–2019 ($MILLION)
73
EUROPE: 1ST GENERATION ELISA MARKET SIZE, BY COUNTRY/REGION, 2012–2019 ($MILLION)
73
ASIA: 1ST GENERATION ELISA MARKET SIZE, BY COUNTRY/REGION, 2012–2019 ($MILLION)
74
TABLE 32
2ND GENERATION ELISA MARKET SIZE, BY REGION, 2012–2019 ($MILLION)
74
TABLE 33
NORTH AMERICA: 2ND GENERATION ELISA MARKET SIZE, BY REGION, 2012–2019 ($MILLION)
75
EUROPE: 2ND GENERATION ELISA MARKET SIZE, BY COUNTRY/REGION, 2012–2019 ($MILLION)
75
ASIA: 2ND GENERATION ELISA MARKET SIZE, BY COUNTRY/REGION, 2012–2019 ($MILLION)
76
TABLE 36
3RD GENERATION ELISA MARKET SIZE, BY REGION, 2012–2019 ($MILLION)
76
TABLE 37
NORTH AMERICA: 3RD GENERATION ELISA MARKET SIZE, BY COUNTRY, 2012–2019 ($MILLION)
77
EUROPE: 3RD GENERATION ELISA MARKET SIZE, BY COUNTRY/REGION, 2012–2019 ($MILLION)
77
ASIA: 3RD GENERATION ELISA MARKET SIZE, BY COUNTRY/REGION, 2012–2019 ($MILLION)
78
TABLE 40
4TH GENERATION ELISA MARKET SIZE, BY REGION, 2012–2019 ($MILLION)
79
TABLE 41
NORTH AMERICA: 4TH GENERATION ELISA MARKET SIZE, BY COUNTRY, 2012–2019 ($MILLION)
80
EUROPE: 4TH GENERATION ELISA MARKET SIZE, BY COUNTRY/REGION, 2012–2019 ($MILLION)
80
ASIA: 4TH GENERATION ELISA MARKET SIZE, BY COUNTRY/REGION, 2012–2019 ($MILLION)
81
TABLE 44
EIAS AND CLIAS MARKET SIZE, BY REGION, 2012–2019 ($MILLION)
81
TABLE 45
NORTH AMERICA: EIAS AND CLIAS MARKET SIZE, BY REGION, 2012–2019 ($MILLION)
82
EUROPE: EIAS AND CLIAS MARKET SIZE, BY COUNTRY/REGION, 2012–2019 ($MILLION)
82
ASIA: EIAS AND CLIAS MARKET SIZE, BY COUNTRY/REGION, 2012–2019 ($MILLION)
83
TABLE 48
NGS MARKET SIZE, BY REGION, 2012–2019 ($MILLION)
83
TABLE 49
NORTH AMERICA: NGS MARKET SIZE, BY REGION, 2012–2019 ($MILLION)
84
TABLE 50
EUROPE: NGS MARKET SIZE, BY COUNTRY/REGION, 2012–2019 ($MILLION)
84
TABLE 51
ASIA: NGS MARKET SIZE, BY COUNTRY/REGION, 2012–2019 ($MILLION)
85
TABLE 52
WESTERN BLOT ASSAY MARKET SIZE, BY REGION, 2012–2019 ($MILLION)
85
TABLE 53
NORTH AMERICA: WESTERN BLOT ASSAY MARKET SIZE, BY COUNTRY, 2012–2019 ($MILLION)
86
EUROPE: WESTERN BLOT ASSAY MARKET SIZE, BY COUNTRY/REGION, 2012–2019 ($MILLION)
86
ASIA: WESTERN BLOT ASSAY MARKET SIZE, BY COUNTRY/REGION, 2012–2019 ($MILLION)
87
BLOOD SCREENING MARKET SIZE, BY PRODUCTS AND SERVICES, 2012–2019 ($MILLION)
89
BLOOD SCREENING REAGENTS MARKET SIZE, BY REGION, 2012–2019 ($MILLION)
91
TABLE 30 TABLE 31
TABLE 34 TABLE 35
TABLE 38 TABLE 39
TABLE 42 TABLE 43
TABLE 46 TABLE 47
TABLE 54 TABLE 55 TABLE 56 TABLE 57
18 © MarketsandMarkets
Blood Screening Market – Forecasts to 2019
TABLE 58
BT 3228
NORTH AMERICA: BLOOD SCREENING REAGENTS MARKET SIZE, BY COUNTRY, 2012–2019 ($MILLION)
91
EUROPE: BLOOD SCREENING REAGENTS MARKET SIZE, BY COUNTRY, 2012–2019 ($MILLION)
91
ASIA: BLOOD SCREENING REAGENTS MARKET SIZE, BY COUNTRY, 2012–2019 ($MILLION)
92
TABLE 61
BLOOD SCREENING REAGENTS MARKET SIZE, BY TYPE, 2012–2019 ($MILLION)
92
TABLE 62
BLOOD SCREENING ELISA REAGENTS MARKET SIZE, BY REGION, 2012–2019 ($MILLION)
93
NORTH AMERICA: BLOOD SCREENING ELISA REAGENTS MARKET SIZE, BY COUNTRY, 2012–2019 ($MILLION)
93
EUROPE: BLOOD SCREENING ELISA REAGENTS MARKET SIZE, BY COUNTRY, 2012–2019 ($MILLION)
94
ASIA: BLOOD SCREENING ELISA REAGENTS MARKET SIZE, BY COUNTRY, 2012–2019 ($MILLION)
94
BLOOD SCREENING ELISA REAGENTS MARKET SIZE, BY TYPE, 2012–2019 ($MILLION)
95
BLOOD SCREENING NAT REAGENTS MARKET SIZE, BY REGION, 2012–2019 ($MILLION)
96
NORTH AMERICA: BLOOD SCREENING NAT REAGENTS MARKET SIZE, BY COUNTRY, 2012–2019 ($MILLION)
97
EUROPE: BLOOD SCREENING NAT REAGENTS MARKET SIZE, BY COUNTRY, 2012–2019 ($MILLION)
97
ASIA: BLOOD SCREENING NAT REAGENTS MARKET SIZE, BY COUNTRY, 2012–2019 ($MILLION)
98
BLOOD SCREENING NAT REAGENTS MARKET SIZE, BY TYPE, 2012–2019 ($MILLION)
99
BLOOD SCREENING OTHER REAGENTS MARKET SIZE, BY REGION, 2012–2019 ($MILLION)
100
NORTH AMERICA: BLOOD SCREENING OTHER REAGENTS MARKET SIZE, BY COUNTRY, 2012–2019 ($MILLION)
100
EUROPE: BLOOD SCREENING OTHER REAGENTS MARKET SIZE, BY COUNTRY, 2012–2019 ($MILLION)
101
ASIA: BLOOD SCREENING OTHER REAGENTS MARKET SIZE, BY COUNTRY, 2012–2019 ($MILLION)
101
BLOOD SCREENING INSTRUMENTS MARKET SIZE, BY REGION, 2012–2019 ($MILLION)
102
NORTH AMERICA: BLOOD SCREENING INSTRUMENTS MARKET SIZE, BY COUNTRY, 2012–2019 ($MILLION)
102
EUROPE: BLOOD SCREENING INSTRUMENTS MARKET SIZE, BY COUNTRY, 2012–2019 ($MILLION)
103
ASIA: BLOOD SCREENING INSTRUMENTS MARKET SIZE, BY COUNTRY, 2012–2019 ($MILLION)
103
BLOOD SCREENING INSTRUMENTS MARKET SIZE, BY MODE OF PURCHASE, 2012–2019 ($MILLION)
104
BLOOD SCREENING SOFTWARE AND SERVICES MARKET SIZE, BY REGION, 2012–2019 ($MILLION)
105
NORTH AMERICA: BLOOD SCREENING SOFTWARE AND SERVICES MARKET SIZE, BY COUNTRY, 2012–2019 ($MILLION)
105
EUROPE: BLOOD SCREENING SOFTWARE AND SERVICES MARKET SIZE, BY REGION, 2012–2019 ($MILLION)
106
TABLE 59 TABLE 60
TABLE 63 TABLE 64 TABLE 65 TABLE 66 TABLE 67 TABLE 68 TABLE 69 TABLE 70 TABLE 71 TABLE 72 TABLE 73 TABLE 74 TABLE 75 TABLE 76 TABLE 77 TABLE 78 TABLE 79 TABLE 80 TABLE 81 TABLE 82 TABLE 83
19 © MarketsandMarkets
Blood Screening Market – Forecasts to 2019
TABLE 84
BT 3228
ASIA: BLOOD SCREENING SOFTWARE AND SERVICES MARKET SIZE, BY COUNTRY, 2012–2019 ($MILLION)
106
TABLE 85
BLOOD SCREENING MARKET SIZE, BY END USER, 2012–2019 ($MILLION)
109
TABLE 86
BLOOD SCREENING MARKET SIZE FOR BLOOD BANKS, BY REGION, 2012–2019 ($MILLION)
110
NORTH AMERICA: BLOOD SCREENING MARKET SIZE FOR BLOOD BANKS, BY COUNTRY, 2012–2019 ($MILLION)
110
EUROPE: BLOOD SCREENING MARKET SIZE FOR BLOOD BANKS, BY COUNTRY, 2012–2019 ($MILLION)
111
ASIA: BLOOD SCREENING MARKET SIZE FOR BLOOD BANKS, BY COUNTRY, 2012–2019 ($MILLION)
111
BLOOD SCREENING MARKET SIZE FOR HOSPITALS, BY REGION, 2012–2019 ($MILLION)
112
NORTH AMERICA: BLOOD SCREENING MARKET SIZE FOR HOSPITALS, BY COUNTRY, 2012–2019 ($MILLION)
113
EUROPE: BLOOD SCREENING MARKET SIZE FOR HOSPITALS, BY COUNTRY, 2012–2019 ($MILLION)
113
ASIA: BLOOD SCREENING MARKET SIZE FOR HOSPITALS, BY COUNTRY, 2012–2019 ($MILLION)
114
TABLE 94
GLOBAL BLOOD SCREENING MARKET SIZE, BY REGION, 2012–2019 ($MILLION)
117
TABLE 95
NORTH AMERICA: BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2012–2019 ($MILLION)
118
EUROPE: BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2012–2019 ($MILLION)
118
TABLE 97
ASIA: BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2012–2019 ($MILLION)
119
TABLE 98
NORTH AMERICA: BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2012–2019 ($MILLION)
120
NORTH AMERICA: BLOOD SCREENING MARKET SIZE FOR NAT, BY TYPE, 2012–2019 ($MILLION)
120
NORTH AMERICA: BLOOD SCREENING MARKET SIZE FOR ELISA, BY TYPE, 2012–2019 ($MILLION)
121
NORTH AMERICA: BLOOD SCREENING MARKET SIZE, BY PRODUCTS AND SERVICES, 2012–2019 ($MILLION)
121
NORTH AMERICA: BLOOD SCREENING MARKET SIZE FOR REAGENTS, BY TYPE, 2012–2019 ($MILLION)
122
NORTH AMERICA: BLOOD SCREENING MARKET SIZE, BY END USER, 2012–2019 ($MILLION)
122
TABLE 104
U.S.: BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2012–2019 ($MILLION)
123
TABLE 105
U.S.: BLOOD SCREENING MARKET SIZE FOR NAT, BY TYPE, 2012–2019 ($MILLION)
123
U.S.: BLOOD SCREENING MARKET SIZE FOR ELISA, BY TYPE, 2012–2019 ($MILLION)
123
U.S.: BLOOD SCREENING MARKET SIZE, BY PRODUCTS & SERVICES, 2012–2019 ($MILLION)
124
U.S.: BLOOD SCREENING MARKET SIZE FOR REAGENTS, BY TYPE, 2012–2019 ($MILLION)
124
TABLE 109
U.S.: BLOOD SCREENING MARKET SIZE, BY END USER, 2012–2019 ($MILLION)
124
TABLE 110
CANADA: BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2012–2019 ($MILLION)
125
CANADA: BLOOD SCREENING MARKET SIZE FOR NAT, BY TYPE, 2012–2019 ($MILLION)
125
TABLE 87 TABLE 88 TABLE 89 TABLE 90 TABLE 91 TABLE 92 TABLE 93
TABLE 96
TABLE 99 TABLE 100 TABLE 101 TABLE 102 TABLE 103
TABLE 106 TABLE 107 TABLE 108
TABLE 111
20 © MarketsandMarkets
Blood Screening Market – Forecasts to 2019
TABLE 112
BT 3228
CANADA: BLOOD SCREENING MARKET SIZE FOR ELISA, BY TYPE, 2012–2019 ($MILLION)
126
CANADA: BLOOD SCREENING MARKET SIZE, BY PRODUCTS & SERVICES, 2012–2019 ($MILLION)
126
CANADA: BLOOD SCREENING MARKET SIZE FOR REAGENTS, BY TYPE, 2012–2019 ($MILLION)
127
CANADA: BLOOD SCREENING MARKET SIZE, BY END USER, 2012–2019 ($MILLION)
127
EUROPE: BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2012–2019 ($MILLION)
128
EUROPE: BLOOD SCREENING MARKET SIZE FOR NAT, BY TYPE, 2012–2019 ($MILLION)
128
EUROPE: BLOOD SCREENING MARKET SIZE FOR ELISA, BY TYPE, 2012–2019 ($MILLION)
129
EUROPE: BLOOD SCREENING MARKET SIZE, BY PRODUCTS AND SERVICES, 2012–2019 ($MILLION)
129
EUROPE: BLOOD SCREENING MARKET SIZE FOR REAGENTS, BY TYPE, 2012–2019 ($MILLION)
130
EUROPE: BLOOD SCREENING MARKET SIZE, BY END USER, 2012–2019 ($MILLION)
130
GERMANY: BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2012–2019 ($MILLION)
131
GERMANY: BLOOD SCREENING MARKET SIZE FOR NAT, BY TYPE, 2012–2019 ($MILLION)
131
GERMANY: BLOOD SCREENING MARKET SIZE FOR ELISA, BY TYPE, 2012–2019 ($MILLION)
132
GERMANY: BLOOD SCREENING MARKET SIZE, BY PRODUCTS & SERVICES, 2012–2019 ($MILLION)
132
GERMANY: BLOOD SCREENING MARKET SIZE FOR REAGENTS, BY TYPE, 2012–2019 ($MILLION)
133
GERMANY: BLOOD SCREENING MARKET SIZE, BY END USER, 2012–2019 ($MILLION)
133
FRANCE: BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2012–2019 ($MILLION)
134
FRANCE: BLOOD SCREENING MARKET SIZE FOR NAT, BY TYPE, 2012–2019 ($MILLION)
134
FRANCE: BLOOD SCREENING MARKET SIZE FOR ELISA, BY TYPE, 2012–2019 ($MILLION)
134
FRANCE: BLOOD SCREENING MARKET SIZE, BY PRODUCTS & SERVICES, 2012–2019 ($MILLION)
135
FRANCE: BLOOD SCREENING MARKET SIZE FOR REAGENTS, BY TYPE, 2012–2019 ($MILLION)
135
FRANCE: BLOOD SCREENING MARKET SIZE, BY END USER, 2012–2019 ($MILLION)
136
TABLE 134
U.K.: BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2012–2019 ($MILLION)
136
TABLE 135
U.K.: BLOOD SCREENING MARKET SIZE FOR NAT, BY TYPE, 2012–2019 ($MILLION)
137
U.K.: BLOOD SCREENING MARKET SIZE FOR ELISA, BY TYPE, 2012–2019 ($MILLION)
137
U.K.: BLOOD SCREENING MARKET SIZE, BY PRODUCTS & SERVICES, 2012–2019 ($MILLION)
138
TABLE 113 TABLE 114 TABLE 115 TABLE 116 TABLE 117 TABLE 118 TABLE 119 TABLE 120 TABLE 121 TABLE 122 TABLE 123 TABLE 124 TABLE 125 TABLE 126 TABLE 127 TABLE 128 TABLE 129 TABLE 130 TABLE 131 TABLE 132 TABLE 133
TABLE 136 TABLE 137
21 © MarketsandMarkets
Blood Screening Market – Forecasts to 2019
TABLE 138
BT 3228
U.K.: BLOOD SCREENING MARKET SIZE FOR REAGENTS, BY TYPE, 2012–2019 ($MILLION)
138
TABLE 139
U.K.: BLOOD SCREENING MARKET SIZE, BY END USER, 2012–2019 ($MILLION)
138
TABLE 140
ITALY: BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2012–2019 ($MILLION)
139
ITALY: BLOOD SCREENING MARKET SIZE FOR NAT, BY TYPE, 2012–2019 ($MILLION)
139
ITALY: BLOOD SCREENING MARKET SIZE FOR ELISA, BY TYPE, 2012–2019 ($MILLION)
140
ITALY: BLOOD SCREENING MARKET SIZE, BY PRODUCTS & SERVICES, 2012–2019 ($MILLION)
140
ITALY: BLOOD SCREENING MARKET SIZE FOR REAGENTS, BY TYPE, 2012–2019 ($MILLION)
141
TABLE 145
ITALY: BLOOD SCREENING MARKET SIZE, BY END USER, 2012–2019 ($MILLION)
141
TABLE 146
SPAIN: BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2012–2019 ($MILLION)
142
SPAIN: BLOOD SCREENING MARKET SIZE FOR NAT, BY TYPE, 2012–2019 ($MILLION)
142
SPAIN: BLOOD SCREENING MARKET SIZE FOR ELISA, BY TYPE, 2012–2019 ($MILLION)
143
SPAIN: BLOOD SCREENING MARKET SIZE, BY PRODUCTS & SERVICES, 2012–2019 ($MILLION)
143
SPAIN: BLOOD SCREENING MARKET SIZE FOR REAGENTS, BY TYPE, 2012–2019 ($MILLION)
144
TABLE 151
SPAIN: BLOOD SCREENING MARKET SIZE, BY END USER, 2012–2019 ($MILLION)
144
TABLE 152
ROE: BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2012–2019 ($MILLION)
145
ROE: BLOOD SCREENING MARKET SIZE FOR NAT, BY TYPE, 2012–2019 ($MILLION)
145
ROE: BLOOD SCREENING MARKET SIZE FOR ELISA, BY TYPE, 2012–2019 ($MILLION)
146
ROE: BLOOD SCREENING MARKET SIZE, BY PRODUCTS & SERVICES, 2012–2019 ($MILLION)
146
ROE: BLOOD SCREENING MARKET SIZE FOR REAGENTS, BY TYPE, 2012–2019 ($MILLION)
147
TABLE 157
ROE: BLOOD SCREENING MARKET SIZE, BY END USER, 2012–2019 ($MILLION)
147
TABLE 158
ASIA: BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2012–2019 ($MILLION)
148
ASIA: BLOOD SCREENING MARKET SIZE FOR NAT, BY TYPE, 2012–2019 ($MILLION)
148
ASIA: BLOOD SCREENING MARKET SIZE FOR ELISA, BY TYPE, 2012–2019 ($MILLION)
149
ASIA: BLOOD SCREENING MARKET SIZE, BY PRODUCTS & SERVICES, 2012–2019 ($MILLION)
149
ASIA: BLOOD SCREENING MARKET SIZE FOR REAGENTS, BY TYPE, 2012–2019 ($MILLION)
150
TABLE 163
ASIA: BLOOD SCREENING MARKET SIZE, BY END USER, 2012–2019 ($MILLION)
150
TABLE 164
JAPAN: BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2012–2019 ($MILLION)
151
JAPAN: BLOOD SCREENING MARKET SIZE FOR NAT, BY TYPE, 2012–2019 ($MILLION)
151
TABLE 141 TABLE 142 TABLE 143 TABLE 144
TABLE 147 TABLE 148 TABLE 149 TABLE 150
TABLE 153 TABLE 154 TABLE 155 TABLE 156
TABLE 159 TABLE 160 TABLE 161 TABLE 162
TABLE 165
22 © MarketsandMarkets
Blood Screening Market – Forecasts to 2019
TABLE 166
BT 3228
JAPAN: BLOOD SCREENING MARKET SIZE FOR ELISA, BY TYPE, 2012–2019 ($MILLION)
151
JAPAN: BLOOD SCREENING MARKET SIZE, BY PRODUCTS & SERVICES, 2012–2019 ($MILLION)
152
JAPAN: BLOOD SCREENING MARKET SIZE FOR REAGENTS, BY TYPE, 2012–2019 ($MILLION)
152
TABLE 169
JAPAN: BLOOD SCREENING MARKET SIZE, BY END USER, 2012–2019 ($MILLION)
153
TABLE 170
CHINA: BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2012–2019 ($MILLION)
154
CHINA: BLOOD SCREENING MARKET SIZE FOR NAT, BY TYPE, 2012–2019 ($MILLION)
154
CHINA: BLOOD SCREENING MARKET SIZE FOR ELISA, BY TYPE, 2012–2019 ($MILLION)
155
CHINA: BLOOD SCREENING MARKET SIZE, BY PRODUCTS & SERVICES, 2012–2019 ($MILLION)
155
CHINA: BLOOD SCREENING MARKET SIZE FOR REAGENTS, BY TYPE, 2012–2019 ($MILLION)
156
TABLE 175
CHINA: BLOOD SCREENING MARKET SIZE, BY END USER, 2012–2019 ($MILLION)
156
TABLE 176
INDIA: BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2012–2019 ($MILLION)
157
INDIA: BLOOD SCREENING MARKET SIZE FOR NAT, BY TYPE, 2012–2019 ($MILLION)
157
INDIA: BLOOD SCREENING MARKET SIZE FOR ELISA, BY TYPE, 2012–2019 ($MILLION)
158
INDIA: BLOOD SCREENING MARKET SIZE, BY PRODUCTS & SERVICES, 2012–2019 ($MILLION)
158
INDIA: BLOOD SCREENING MARKET SIZE FOR REAGENTS, BY TYPE, 2012–2019 ($MILLION)
159
TABLE 181
INDIA: BLOOD SCREENING MARKET SIZE, BY END USER, 2012–2019 ($MILLION)
159
TABLE 182
ROA: BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2012–2019 ($MILLION)
160
ROA: BLOOD SCREENING MARKET SIZE FOR NAT, BY TYPE, 2012–2019 ($MILLION)
160
ROA: BLOOD SCREENING MARKET SIZE FOR ELISA, BY TYPE, 2012–2019 ($MILLION)
161
ROA: BLOOD SCREENING MARKET SIZE, BY PRODUCTS & SERVICES, 2012–2019 ($MILLION)
161
ROA: BLOOD SCREENING MARKET SIZE FOR REAGENTS, BY TYPE, 2012–2019 ($MILLION)
162
TABLE 187
ROA: BLOOD SCREENING MARKET SIZE, BY END USER, 2012–2019 ($MILLION)
162
TABLE 188
ROW: BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2012–2019 ($MILLION)
163
ROW: BLOOD SCREENING MARKET SIZE FOR NAT, BY TYPE, 2012–2019 ($MILLION)
163
ROW: BLOOD SCREENING MARKET SIZE FOR ELISA, BY TYPE, 2012–2019 ($MILLION)
164
ROW: BLOOD SCREENING MARKET SIZE, BY PRODUCTS & SERVICES, 2012–2019 ($MILLION)
164
ROW: BLOOD SCREENING MARKET SIZE FOR REAGENTS, BY TYPE, 2012–2019 ($MILLION)
165
ROW: BLOOD SCREENING MARKET SIZE, BY END USER, 2012–2019 ($MILLION)
165
TABLE 167 TABLE 168
TABLE 171 TABLE 172 TABLE 173 TABLE 174
TABLE 177 TABLE 178 TABLE 179 TABLE 180
TABLE 183 TABLE 184 TABLE 185 TABLE 186
TABLE 189 TABLE 190 TABLE 191 TABLE 192 TABLE 193
23 © MarketsandMarkets
Blood Screening Market – Forecasts to 2019
BT 3228
TABLE 194
RECENT DEVELOPMENTS, 2011–2014
170
TABLE 195
RECENT DEVELOPMENTS, 2011–2014
171
TABLE 196
RECENT DEVELOPMENTS, 2011–2015
172
TABLE 197
RECENT DEVELOPMENTS, 2011–2014
173
24 © MarketsandMarkets
Blood Screening Market – Forecasts to 2019
BT 3228
LIST OF FIGURES FIGURE 1
RESEARCH METHODOLOGY
23
FIGURE 2
BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
26
FIGURE 3
BOTTOM-UP APPROACH
27
FIGURE 4
TOP-DOWN APPROACH
28
FIGURE 5
DATA TRIANGULATION METHODOLOGY
29
FIGURE 6
BLOOD SCREENING MARKET SNAPSHOT, BY TECHNOLOGY (2014 VS. 2019)
31
FIGURE 7
REAGENTS SEGMENT TO DOMINATE THE BLOOD SCREENING MARKET DURING THE FORECAST PERIOD
32
FOURTH-GENERATION ELISA IS LARGEST SEGMENT OF THE BLOOD SCREENING MARKET
32
BLOOD BANKS IS THE FASTEST-GROWING END-USER SEGMENT OF THE BLOOD SCREENING MARKET DURING THE FORECASTED PERIOD
33
FIGURE 10
GEOGRAPHICAL SNAPSHOT OF THE GLOBAL BLOOD SCREENING MARKET
34
FIGURE 11
NAT SEGMENT TO OFFER ATTRACTIVE GROWTH OPPORTUNITIES
35
FIGURE 12
THE BLOOD SCREENING REAGENTS SEGMENT TO GROW AT THE HIGHEST RATE DURING THE FORECAST PERIOD
36
NAT REAGENTS CONTRIBUTE THE HIGHEST SHARE TO THE BLOOD SCREENING REAGENTS MARKET
37
THE 4TH GENERATION ELISA SEGMENT IS EXPECTED TO GROW AT THE HIGHEST CAGR IN ASIA DURING THE FORECAST PERIOD
38
THE BLOOD BANKS SEGMENT TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD
39
FIGURE 16
CHINA TO WITNESS THE HIGHEST GROWTH IN THE FORECAST PERIOD
40
FIGURE 17
TECHNOLOGICAL INNOVATION AND DIFFERENTIATED PRODUCTS ARE INCREASING COMPETITION AMONG MARKET PLAYERS
55
NAT TESTING WILL CONTINUE TO DOMINATE THE MARKET DURING THE FORECAST PERIOD
58
REAL-TIME PCR EXPECTED TO GROW AT A DOUBLE-DIGIT CAGR FROM 2014 TO 2019
61
FIGURE 20
ASIAN 4TH GENERATION ELISA MARKET EXPECTED TO DOUBLE BY 2019
79
FIGURE 21
REAGENTS SEGMENT WILL CONTINUE TO DOMINATE THE BLOOD SCREENING MARKET DURING FORECAST PERIOD
89
ASIA IS THE FASTEST-GROWING REGION IN THE BLOOD SCREENING REAGENT MARKET
90
CHINA TO WITNESS THE HIGHEST GROWTH IN THE BLOOD SCREENING NAT REAGENTS MARKET IN ASIA
98
FIGURE 24
BLOOD SCREENING MARKET SEGMENTATION, BY END USER
108
FIGURE 25
BLOOD BANKS SEGMENT WILL CONTINUE TO DOMINATE THE BLOOD SCREENING MARKET DURING THE FORECAST PERIOD
108
REGIONALSNAPSHOT: EMERGING MARKETS SUCH AS CHINA, INDIA AND JAPAN OFFER SIGNIFICANT GROWTH OPPORTUNITIES IN THE BLOOD SCREENING MARKET
117
NORTH AMERICA: MARKET GROWTH WILL BE DRIVEN BY INNOVATIVE BLOOD SCREENING INSTRUMENTS AND REAGENTS
119
FIGURE 8 FIGURE 9
FIGURE 13 FIGURE 14 FIGURE 15
FIGURE 18 FIGURE 19
FIGURE 22 FIGURE 23
FIGURE 26
FIGURE 27
25 © MarketsandMarkets
Blood Screening Market – Forecasts to 2019
FIGURE 28
BT 3228
CHINA OFFERS IMMENSE GROWTH OPPORTUNITIES FOR THE BLOOD SCREENING MARKET
153
NEW PRODUCT LAUNCHES WAS THE KEY GROWTH STRATEGY ADOPTED BY LEADING PLAYERS
166
FIGURE 30
BLOOD SCREENING MARKET SHARE ANALYSIS FOR NAT, BY KEY PLAYER, 2014
167
FIGURE 31
BLOOD SCREENING MARKET SHARE ANALYSIS, BY KEY PLAYER, 2014
168
FIGURE 32
BATTLE FOR MARKET SHARE: NEW PRODUCT LAUNCHES WAS THE KEY STRATEGY
169
FIGURE 33
PRODUCT BENCHMARKING FOR TOP 5 PLAYERS
174
FIGURE 34
GRIFOLS: COMPANY SNAPSHOT
175
FIGURE 35
ROCHE DIAGNOSTICS: COMPANY SNAPSHOT
178
FIGURE 36
ABBOTT LABORATORIES: COMPANY SNAPSHOT
181
FIGURE 37
BIOMÉRIEUX: COMPANY SNAPSHOT
184
FIGURE 38
BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT
187
FIGURE 39
SIEMENS AG : COMPANY SNAPSHOT
190
FIGURE 40
THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT
194
FIGURE 41
DANAHER CORPORATION: COMPANY SNAPSHOT
196
FIGURE 42
BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT
198
FIGURE 29
26 © MarketsandMarkets
Blood Screening Market – Forecasts to 2019
BT 3228
SAMPLE TABLES TABLE 1
NORTH AMERICA: ELISA MARKET SIZE, BY COUNTRY, 2012–2019 ($MILLION) Country
2012
2013
2014
CAGR% (2014-2019)
2019
U.S.
XX
XX
XX
XX
XX
Canada
XX
XX
XX
XX
XX
Total
XX
XX
XX
XX
XX
Note: e-Estimated, p-Projected Source: Annual Reports, SEC Filings, Press Releases, Investor Presentations, World Health Organization (WHO), United States Food and Drug Administration (USFDA), Centers for Disease Control and Prevention (CDC), Red Cross Society, AVERT, Expert Interviews, and MarketsandMarkets Analysis
In 2014, the U.S. commanded the largest share of ~XX% of the North American blood screening ELISA market. This geographic segment is poised to reach $XX million by 2019 from $XX million in 2014, at a CAGR of XX% from 2014 to 2019.
TABLE 2
NORTH AMERICA: RAPID TEST (CARD METHODOLOGY) MARKET SIZE, BY COUNTRY, 2012–2019 ($MILLION) Country
2012
2013
2014
CAGR% (2014-2019)
2019
U.S.
XX
XX
XX
XX
XX
Canada
XX
XX
XX
XX
XX
Total
XX
XX
XX
XX
XX
Note: e-Estimated, p-Projected Source: Annual Reports, SEC Filings, Press Releases, Investor Presentations, World Health Organization (WHO), United States Food and Drug Administration (USFDA), Centers for Disease Control and Prevention (CDC), Red Cross Society, AVERT, Expert Interviews, and MarketsandMarkets Analysis
In 2014, the U.S. commanded the largest share of ~XX% of the North American blood screening Rapid Test (Card Methodology) market. This geographic segment is poised to reach $XX million by 2019 from $XX million in 2014, at a CAGR of XX% from 2014 to 2019.
27 © MarketsandMarkets
Blood Screening Market – Forecasts to 2019
TABLE 3
BT 3228
EUROPE: 1ST GENERATION ELISA MARKET SIZE, BY COUNTRY/REGION, 2012–2019 ($MILLION)
Country/Region
2012
2013
2014
CAGR% (2014-2019)
2019
Germany
XX
XX
XX
XX
XX
France
XX
XX
XX
XX
XX
U.K.
XX
XX
XX
XX
XX
Italy
XX
XX
XX
XX
XX
Spain
XX
XX
XX
XX
XX
Rest of Europe
XX
XX
XX
XX
XX
Total
XX
XX
XX
XX
XX
Note: e-Estimated, p-Projected Source: Annual Reports, SEC Filings, Press Releases, Investor Presentations, World Health Organization (WHO), United States Food and Drug Administration (USFDA), Centers for Disease Control and Prevention (CDC), Red Cross Society, AVERT, Expert Interviews, and MarketsandMarkets Analysis
In 2014, Germany commanded the largest share of ~XX% of the European blood screening 1st generation ELISA market. This geographic segment is poised to reach $XX million by 2019 from $XX million in 2014, at a CAGR of XX% from 2014 to 2019.
28 © MarketsandMarkets
Blood Screening Market – Forecasts to 2019
BT 3228
RELATED REPORTS No.
Report Title
Published Date
Molecular Diagnostics Market 1
By Application (Infectious Disease, Oncology, Genetics, Microbiology), Technology (PCR, INAAT, DNA Sequencing), End User (Hospital, Laboratories), Product (Instruments, Reagent, Service, Software) - Global Forecasts to 2018
June 2014
http://www.marketsandmarkets.com/Market-Reports/molecular-diagnostic-market833.html?gclid=Cj0KEQiA1NWnBRDchObfnYrbo78BEiQA2jqBfaxL2lDEvZRojHQRoVgUE0D9kyJvziFRO2No2OhbuEaAgoK8P8HAQ
In Vitro Diagnostic (IVD) Market
2
[Instruments, Reagents & Data Management Systems] [Technique (Immunoassay, Clinical Chemistry, Molecular Diagnostics, Haematology) & Applications (Diabetes, Infectious Diseases, Cancer & Cardiology)] Systems, End Users] – Forecast To 2017
July 2013
http://www.marketsandmarkets.com/Market-Reports/ivd-in-vitro-diagnostics-market703.html?gclid=Cj0KEQiA1NWnBRDchObfnYrbo78BEiQA2jqBWBwpFgMeajSy4_RNDiuycUS_94yA5-LO6UVrOeXlUQaArMh8P8HAQ
29 © MarketsandMarkets
Blood Screening Market â&#x20AC;&#x201C; Forecasts to 2019
BT 3228
Disclaimer: MarketsandMarkets strategic analysis services are limited publications containing valuable market information provided to a select group of customers in response to orders. Our customers acknowledge, when ordering, that MarketsandMarkets strategic analysis services are for our customersâ&#x20AC;&#x2122; internal use and not for general publication or disclosure to third parties. Quantitative market information is based primarily on interviews and therefore, is subject to fluctuation. MarketsandMarkets does not endorse any vendor, product or service depicted in its research publications. MarketsandMarkets strategic analysis publications consist of the opinions of MarketsandMarkets' research and should not be construed as statements of fact. MarketsandMarkets disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose. MarketsandMarkets takes no responsibility for any incorrect information supplied to us by manufacturers or users. All trademarks, copyrights and other forms of intellectual property belong to their respective owners and may be protected by copyright. Under no circumstance may any of these be reproduced in any form without the prior written agreement of their owner. No part of this strategic analysis service may be given, lent, resold or disclosed to non-customers without written permission. Reproduction and/or transmission in any form and by any means including photocopying, mechanical, electronic, recording or otherwise, without the permission of the publisher is prohibited.
For information regarding permission, contact: Tel: 1-888-600-6441 Email: sales@marketsandmarkets.com
30 Š MarketsandMarkets